On October 18, 2024, Aimed Alliance sent a letter to the Maryland Legislative Policy Committee, urging it to make major improvements to the Maryland’s Prescription Drug Affordability Board’s Action Plan. Aimed Alliance specifically requested that the Board revise its plan to incorporate patient perspectives by ensuring that feedback from patients, caregivers, and providers is considered in all affordability assessments and that robust data is collected from advocacy and patient organizations.
The letter also called for the Board to maintain ongoing engagement with diverse stakeholders, including patients, caregivers, and providers, beyond the initial cost-setting process. Additionally, Aimed Alliance urged the Committee to ensure that any cost savings achieved from affordability measures directly reduce consumer drug costs or cost-sharing requirements. Finally, Aimed Alliance advised the Committee to prohibit the use of quality-adjusted life years (QALYs) in cost-effectiveness analyses to avoid any discriminatory impact on individuals with disabilities and chronic conditions. Read the letter here.
Last Updated on November 5, 2024 by Aimed Alliance
